تحميل...
Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor
BACKGROUND: Dermatologic adverse events (AEs) are some of the most frequently observed toxicities of immune-checkpoint inhibitor therapy, but have received little attention. The drugs, pembrolizumab and nivolumab are recently approved inhibitors of the PD-1 receptor that have overlapping AE profiles...
محفوظ في:
| الحاوية / القاعدة: | Eur J Cancer |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
2016
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4998047/ https://ncbi.nlm.nih.gov/pubmed/27043866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2016.02.010 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|